Advances on treatment of myasthenia gravis / 中国实用内科杂志

ABSTRACT

Myasthenia gravis(MG)is an acquired autoimmune disease,which is mediated by nicotinic acetylcholine receptor(AChR)antibody,depends on cellular immunity and involves some complements.It mainly affects AChR on the postsynaptic membrane at the neuromuscular junction(NMJ).Various therapeutic methods have been used in the treatment of MG,but current therapeutic methods can not do well when used alone,and most current drugs have major side effects due to immunosuppression,We expect that novel therapies be discovered.